![]() John is a highly regarded academic physician scientist. He was elected to the American Association of Physicians (AAP) in 2016, received scientific accomplishment awards from the American Thoracic Society in 20, and was awarded the European Respiratory Society (ERS) Gold Medal in Asthma in 2019 in recognition of his excellence in asthma research. ![]() His clinical research is enabled by methods his group has optimized for application in human studies to advance knowledge about patterns of airway inflammation and pathologic airway mucus gels. His clinical research unit and laboratory aims to uncover disease mechanisms and to develop disease biomarkers and novel treatments for airway disease. John’s research program has been continuously funded by the NIH for over 25 years. John also directs the UCSF Airway Clinical Research Center which focuses on human-based studies of disease mechanisms in asthma, COPD, and cystic fibrosis. He directs the Severe Asthma Faculty Practice at UCSF where he manages patients with complex asthma who need careful diagnostic evaluation and tailored treatment, including with therapeutic proteins. Stulbarg Endowed Chair in Pulmonary Medicine at the University of California, San Francisco. John Fahy is Professor of Medicine and the Michael S. from the Fisher School of Business as well as a B.S. He supported the sale of the company to Shire for $2.6B in 2007. Prior to joining Clinical Data, Jim served as the Vice President of Sales and Marketing for New River Pharmaceuticals wherein led the launch plan for Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD. ![]() While at Clinical data, Jim was responsible for creating and executing the plan that led to the company’s sale to Forest Labs in 2011 for $1.2B. Jim was responsible for negotiating multiple technology and product licenses from Stanford, UPenn/CHOP, Merck, BMS, JNJ, and Nippon Kayaku.Īdditionally, Jim served as Chief Commercial Officer at Clinical Data and Halozyme Therapeutics from 2007 to 20 to 2014, respectively. He was also responsible for Global Business Development/ Alliance Management, Commercial Analysis and Manufacturing for five orphan drug programs and four separate products including small molecules, a large molecule and a peptide. Jim initially led corporate development and the IPO process for Eiger raising over $200M from 2015-2019. Jim joins us from Eiger Biopharmaceuticals, a publicly traded company, where he served as Chief Business Officer from August 2014 to July 2021. Jim is a seasoned biotech executive with over 25 years of experience working for emerging biotechnology and large pharma companies. Kelly received her Master’s degree In Statistics from Florida State University. ![]() Kelly has been on teams leading to 4 FDA approvals, and has participated in meetings with advisory boards as well as US, EU, and UK regulatory authorities. At Amgen, she supported the approval of the BLA for NEUPOGEN ®.ĭuring her career, Kelly has been responsible for teams with a wide array of clinical development functions and involved in all phases of development. Over her career, she has worked with the Cystic Fibrosis Foundation Clinical Trials Network and was instrumental in the development and approval of the inhaled antibiotic therapies Cayston® at Corus and TOBI® at PathoGenesis, both for the treatment of pseudomonal airway infections in patients with cystic fibrosis. Prior to her current role, Kelly was Senior Vice President of Clinical Development and Operations at Avalyn Pharma working to develop an inhaled anti-fibrotic therapy for interstitial lung disease. ![]() In her current role as Head of Clinical Development, Kelly provides strategic direction for the executive team and oversite and leadership for clinical development activities at Aer. Kelly has over 25 years of industry experience and over 15 years working in respiratory diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |